Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Wei Yuan(Shanghai Public Health Clinical Center), Bora Gürel(Institute of Cancer Research), Rita Pereira(Institute of Cancer Research), Christina Guo(Peter MacCallum Cancer Centre), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Mateus Crespo(Institute of Cancer Research), Jan Rekowski(Institute of Cancer Research), Carlo Messina(Royal Marsden NHS Foundation Trust), Susana Miranda(Royal Marsden NHS Foundation Trust), Mattia Rediti(Université Libre de Bruxelles), Ruth Riisnaes(Institute of Cancer Research), Adam Sharp(Institute of Cancer Research), Núria Porta, Ana Ferreira(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Maialen Barrero(Royal Marsden NHS Foundation Trust), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Maria D. Fenor de la Maza(Royal Marsden NHS Foundation Trust), Alec Paschalis(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Khobe Chandran(Royal Marsden NHS Foundation Trust), Maryou Lambros(Institute of Cancer Research), Cláudia Bertan(Institute of Cancer Research), Juliet Carmichael(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research)
Cited by 100
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k